angiotensin II-induced calcium signaling in striatal neurons Rafael Rivas-Santisteban , Ana Muñoz , Jaume Lillo , Iu Raïch , Ana Rodríguez-Pérez , Gemma Navarro , José Labandeira-García , Rafael Franco Endomembrane

Breakthroughs this week: Eli Lilly cuts Zepbound prices; GNAI1 missense mutation study; rapid Gαs endosomal translocation. 🔍 This Week in Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly

include: Abalone Bio · AbbVie · Biagon · Biolexis Therapeutics · Confo Therapeutics · Eli Lilly day brings together teams from Nabla Bio, Abalone Bio, Biagon, Iambic Therapeutics, Lembas, and Eli Lilly

After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.

This conversation follows Martin Marro, head of cell pharmacology in obesity research at Eli Lilly, through Martin Marro is Head of Cell Pharmacology and Executive Director of the Obesity Research Group at Eli Lilly

of new drugs targeting specific receptors for various diseases, with Arthur sharing insights on Eli Lilly's